In a move to capture part of the rapidly expanding ophthalmic pharmaceuticals market in India, Bausch + Lomb announced plans to launch a pharmaceutical business in India through a strategic agreement with Micro Labs (Bangalore, India).
The partnership will provide Bausch + Lomb with manufacturing capabilities in the region that will speed the introduction of new prescription and over-the-counter medicines targeted at a wide range of ocular diseases, according to a Bausch + Lomb news release. The company will also establish sales and marketing teams in India and deliver practitioner and patient education programs designed to improve the quality of, and access to, eye care. Additionally, the companies will introduce up to six new pharmaceutical eye drops including Moxisurge, Aquasurge, Aquasurge Max, Bromvue, Ketovue, and Moxisurge-KT.
– Compiled by Steve Daily, News Editor; and Callan Navitsky, Assistant Editor
TOP 5 ARTICLES FROM 2011
- Blue-Violet Subjective Color Changes After Crystalens Implantation
Counseling patients prior to implantation is crucial.
By Peter J. Cornell, MD
- Pros and Cons of Topical Steroids for Viral Conjunctivitis
In most cases, other therapeutic alternatives may be preferable initially.
By David A. Goldman, MD; and Ravi Patel, MD
- Femosecond Lasers for Cataract Sugery: When Will Laser Cataract Surgery Be a Routine Procedure?
Only a few surgeons have experience using femtosecond lasers for cataract surgery.
By LAURA STRAUB, EDITOR-IN-CHIEF
- The Future of Corneal Collagen Crosslinking
Key opinion leaders address benefits of this state-of-the-art treatment during a roundtable discussion held at the 2010 ESCRS meeting in Paris.
By Arthur B. Cummings, MB ChB, FCS(SA), MMed(Ophth), FRCS(Edin); Sheraz M. Daya, MD, FACP, FACS, FRCS(Ed), FRCOphth; A. John Kanellopoulos, MD; Antonio Leccisotti, MD, PhD; Michael Mrochen, PhD; Roy S. Rubinfeld, MD; Theo Seiler, MD, PhD; Aleksander Stojanovic, MD; and William B. Trattler, MD
- Treating the Nonhealing Epithelial Defect
An overview of standard and investigational therapies for persistent corneal epithelial defects.
By Bennie H. Jeng, MD